Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer

Breast Cancer Research and Treatment

Volumn 143, Issue 1, 2014, Pages 189-201

  Liu, Yanhong ^a   Zhou, Renke ^a   Baumbusch, Lars O ^b   Tsavachidis, Spyros ^a   Brewster, Abenaa M ^c   Do, Kim Anh ^c   Sahin, Aysegul ^c   Hortobagyi, Gabriel N ^c   Taube, Joseph H ^c   Mani, Sendurai A ^c   Aarøe, Jørgen ^b,d   Wärnberg, Fredrik ^e   Børresen Dale, Anne Lise ^b,d   Mills, Gordon B ^c   Thompson, Patricia A ^f   Bondy, Melissa L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e UPPSALA UNIVERSITY   (Sweden)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

Bone metastasis; Breast cancer; Copy number imbalances; Molecular inversion probe array; Non bone metastasis

Indexed keywords

ADULT; ALGORITHM; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER STAGING; CHROMOSOME 10Q; CHROMOSOME 11Q; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME 1Q; CHROMOSOME 2P; CHROMOSOME 3Q; CHROMOSOME 7Q; CHROMOSOME 8P; CHROMOSOME LOSS; CHROMOSOME XP; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER IMBALANCE; FEMALE; GENE DOSAGE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LOW RISK POPULATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MOLECULAR PROBE; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; WHOLE GENOME MOLECULAR INVERSION PROBE ARRAY;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS;

EID: 84892830266     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2796-3     Document Type: Article

References (37)

1. American Cancer Society (2010). Breast cancer facts and figures 2009-2010. http://www.cancer.org/acs/groups/content/@nho/documents/document/ f861009final90809pdf.pdf)
2. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s-6249s. doi: 10.1158/1078-0432.CCR-06-0931
3. Paget S (1989) The distribution of secondary growths in cancer of the breast (1889). Cancer Metastasis Rev 8(2):98-101
4. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537-549. doi: S1535610803001326
5. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33(1):49-54. doi: 10.1038/ng1060ng1060
6. Evans AJ, James JJ, Cornford EJ, Chan SY, Burrell HC, Pinder SE, Gutteridge E, Robertson JF, Hornbuckle J, Cheung KL (2004) Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 16(5):345-349
7. Duchnowska R, Szczylik C (2005) Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 31(4):312-318. doi: 10.1016/j.ctrv.2005.04.008
8. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, Crowe JP, Choueiri TK, Dawson AE, Budd GT, Tubbs RR, Casey G, Weil RJ (2006) Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 30(9):1097-1104. doi: 10.1097/01.pas.0000213306.05811.b900000478- 200609000-00005
9. Nam BH, Kim SY, Han HS, Kwon Y, Lee KS, Kim TH, Ro J (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10(1):R20. doi: 10.1186/bcr1870
10. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459(7249):1005-1009. doi: 10.1038/nature08021
11. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, Massague J (2005) Genes that mediate breast cancer metastasis to lung. Nature 436(7050):518-524. doi: 10.1038/nature03799
12. Singletary SE, Walsh G, Vauthey JN, Curley S, Sawaya R, Weber KL, Meric F, Hortobagyi GN (2003) A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8(3):241-251
13. Brewster AM, Do KA, Thompson PA, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML (2007) Relationship between epidemiologic risk factors and breast cancer recurrence. J Clin Oncol 25(28):4438-4444. doi: 10.1200/JCO.2007.10.6815
14. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML (2011) Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One 6(8):e23543. doi: 10.1371/journal.pone.0023543
15. Binder H, Schumacher M (2008) Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models. BMC Bioinformatics 9:14. doi: 10.1186/1471-2105-9-14
16. Hoeting J, Madigan D, Raftery AE, Volinsky C (1999) Bayesian model averaging: a tutorial. Stat Sci 14:382-417
17. Volinsky C, Madigan D, Raftery A, Kronmal R (1997) Bayesian model averaging in proportional hazard models: assessing the risk of a stroke. Appl Stat 46:433-448
18. Rodriguez C, Hughes-Davies L, Valles H, Orsetti B, Cuny M, Ursule L, Kouzarides T, Theillet C (2004) Amplification of the BRCA2 pathway gene EMSY in sporadic breast cancer is related to negative outcome. Clin Cancer Res 10(17):5785-5791. doi: 10.1158/1078-0432.CCR-03-04100/17/5785
19. Szepetowski P, Ollendorff V, Grosgeorge J, Courseaux A, Birnbaum D, Theillet C, Gaudray P (1992) DNA amplification at 11q13.5-q14 in human breast cancer. Oncogene 7(12):2513-2517
20. Bekri S, Adelaide J, Merscher S, Grosgeorge J, Caroli-Bosc F, Perucca-Lostanlen D, Kelley PM, Pebusque MJ, Theillet C, Birnbaum D, Gaudray P (1997) Detailed map of a region commonly amplified at 11q13- >q14 in human breast carcinoma. Cytogenet Cell Genet 79(1-2):125-131
21. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Haga S, Kajiwara T, Nakamura Y (2001) Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 7(4):876-882
22. Utada Y, Haga S, Kajiwara T, Kasumi F, Sakamoto G, Nakamura Y, Emi M (2000) Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas. Cancer 88(6):1410-1416. doi: 10.1002/(SICI)1097-0142(20000315)
23. Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M, Weiner H, Ruiz i, Altaba A (2001) The sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 128(24):5201-5212
24. Liu CJ, Lin SC, Chen YJ, Chang KM, Chang KW (2006) Array-comparative genomic hybridization to detect genomewide changes in microdissected primary and metastatic oral squamous cell carcinomas. Mol Carcinog 45(10):721-731. doi: 10.1002/mc.20213
25. Martinez-Cardus A, Martinez-Balibrea E, Bandres E, Malumbres R, Gines A, Manzano JL, Taron M, Garcia-Foncillas J, Abad A (2009) Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancer. Mol Cancer Ther 8(1):194-202. doi: 10.1158/1535-7163.MCT-08-0659
26. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, Werner M (2007) Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med (Berl) 85(3):293-304. doi: 10.1007/s00109-006-0126-5
27. Maire G, Forus A, Foa C, Bjerkehagen B, Mainguene C, Kresse SH, Myklebost O, Pedeutour F (2003) 11q13 alterations in two cases of hibernoma: large heterozygous deletions and rearrangement breakpoints near GARP in 11q13.5. Genes Chromosomes Cancer 37(4):389-395. doi: 10.1002/gcc.10223
28. Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, Milner J, Brown LA, Hsu F, Gilks B, Nielsen T, Schulzer M, Chia S, Ragaz J, Cahn A, Linger L, Ozdag H, Cattaneo E, Jordanova ES, Schuuring E, Yu DS, Venkitaraman A, Ponder B, Doherty A, Aparicio S, Bentley D, Theillet C, Ponting CP, Caldas C, Kouzarides T (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115(5):523-535. doi: S0092867403009309
29. Surawska H, Ma PC, Salgia R (2004) The role of Ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15(6):419-433. doi: 10.1016/j.cytogfr. 2004.09.002
30. Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C, Hua S, Negre N, Ludwig M, Stricker T, Al-Ahmadie HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T, Rzhetsky A, White KP (2009) Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 323(5918):1218-1222. doi: 10.1126/science.1157669
31. Lee J, Sayegh J, Daniel J, Clarke S, Bedford MT (2005) PRMT8, a new membrane-bound tissue-specific member of the protein arginine methyltransferase family. J Biol Chem 280(38):32890-32896. doi: 10.1074/jbc.M506944200
32. Goodison S, Yuan J, Sloan D, Kim R, Li C, Popescu NC, Urquidi V (2005) The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 65(14):6042-6053. doi: 10.1158/0008-5472.CAN-04-3043
33. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, van der Heijden MS, Parmigiani G, Yan H, Wang TL, Riggins G, Powell SM, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 304(5674):1164-1166. doi: 10.1126/science.1096096
34. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grutzmann R, Allgayer H, Post S, Gretz N (2007) Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 97(10):1432-1440. doi: 10.1038/sj.bjc.6604031
35. Batlle E, Bacani J, Begthel H, Jonkheer S, Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T, Gallinger S, Pals S, Clevers H (2005) EphB receptor activity suppresses colorectal cancer progression. Nature 435(7045):1126-1130. doi: 10.1038/nature03626
36. Sheng Z, Wang J, Dong Y, Ma H, Zhou H, Sugimura H, Lu G, Zhou X (2008) EphB1 is underexpressed in poorly differentiated colorectal cancers. Pathobiology 75(5):274-280. doi: 10.1159/000151707
37. Nakamoto M, Bergemann AD (2002) Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech 59(1):58-67. doi: 10.1002/jemt.10177